Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ)

sabrient systems

breaking out of cup and handle base

Xyrem is going to pull in a fortune for Jazz Pharmaceuticals (JAZZ) over the next 3 years.

Xyrem is Sodium Oxybate of which is used to prevent Cataplexy of which is muscle weakness that happens suddenly, and last for short periods of time in patients of who have Narcolepsy a sleep disorder that may cause extreme sleepiness, and uncontrollable urges to sleep during daily activities, + Cataplexy. The facts are more, and more adults, and young adults in their early 20's are getting diagnosed with Narcolepsy, and Cataplexy. With the fact that Xyrem is the only known drug out on the market to help in the treatment of Cataplexy makes it a hot item. Did I mention the Tag Price on this is close to $3000.00 a month, in some cases with patients suffering worse, close to $5000.00

Xyrem is protected by eight patents related to the product's formulation and Jazz Pharmaceuticals' distribution system. These patents expire from 2019 to 2024

"The FDA said it reviewed Jazz Pharmaceuticals' response ....... the response lacks sufficient corrective actions. The FDA told Jazz its response fails to develop adequate written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse drug experiences to the agency. "You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, injunction. FDA may re-inspect to verify corrective actions have been completed," the FDA said in the letter. (JAZZ)"

Answer yourself this question: where is the answer from Jazz to the FDA? how come it is not on their website or being published in the wire?? the letter was sent by the FDA on 10/11/11, and it's been more than 15 days!! Is management staying quiet until they unload their shares, then leave the retail investor in the hole?!

How about trading at 10.5 times 2012 estimates. Nice....

value screen

revenues are growing 60% per year but PE is only 31, implying <10% growth rate.

Next quarter expect:
REV - $66M
NET - $26M
EPS - $0.63
R^2 = 0.95
Fair value = $100+

Increasing demand for products.

It's no secret that the technicals are a bloody mess, but based on the fundamentals alone this company looks like a very probably double. I'm basing this on the fact that Xyrem has been growing considerably faster than anyone had accounted for and Luvox continues to offer a nice supplement to the bottom line. Think about this - even with the earnings beats, Jazz is trading at just 6.6 times 2012 earnings despite revenue growth of 44% in 2011 and 26% in 2012. How about a PEG Ratio of just 0.68 based on 5-year growth estimates? How this company is not trading north of $55 or actively being courted by a larger pharmaceutical name is beyond me. Don't believe me? Believe this guy:

http://www.fool.com/investing/high-growth/2011/05/18/10-mid-caps-to-rule-them-all.aspx?source=itxsitmot0000001&lidx=1

Oh wait, that's me too! Guess I must really like this company huh?

TMFUltraLong

will be spitting cash all year with nowhere to put it. Look for a special dividend or acquisition late in the year.

Relative Pullback Likely Complete, Rise to Resume

Increasing sales of existing drugs Xyrem and Luvox with additional products in late stage pipline that should power growth through 2012.

Hmmmmm.

P/E 45.07
P/S 7.73
P/B 43.88
No ROE
LTD/E 0.81
D/E 1.57

Why is this stock up 196% in one year?

great products

Foolish10.

outperform

Jazz around $16 making me Dizzy - favors the shorts from here

Looming FDA approvial

Garbage. Garbage. Garbage!!! See what happens if they fail a drug trial!